Unity Biotechnology Inc $ 6.36 0.71 (12.57%)
Warning! GuruFocus has detected 2 Severe warning signs with UBX. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Unity Biotechnology Inc () from 2018 to Nov 27 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Unity Biotechnology stock (UBX) PE ratio as of Nov 27 2020 is 0. More Details
Unity Biotechnology PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Unity Biotechnology PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:MEIP NAS:WVE NAS:OVID NAS:MGTA NAS:OCUL NAS:ETNB NAS:PDLI NAS:STRO NAS:SPPI NAS:DTIL OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases and pulmonary diseases.